Research Article| Volume 4, SUPPLEMENT 3, S117-S120, January 2004

Gemcitabine and Trastuzumab Combinations for Patients with Metastatic Breast Cancer Overexpressing HER2/neu

      This paper is only available as a PDF. To read, Please Download here.


      In HER2/neu-positive metastatic breast cancer, the combination of chemotherapy and trastuzumab has become a standard of care. This review discusses HER2/neu overexpression in breast cancer and the use of trastuzumab-based therapies. Specifically, the rationale for a gemcitabine/trastuzumab combination in this disease entity and the available clinical data on the use of the combination are discussed. Response rates of 12%-42% have been seen with single-agent gemcitabine and 37%-62% with trastuzumab/gemcitabine combinations. Further work is currently ongoing to examine this promising combination.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Breast Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Revillion F
        • Bonneterre J
        • Peyrat JP
        ERBB2 oncogene in human breast cancer and its clinical significance.
        Eur J Cancer. 1998; 34: 791-808
        • Slamon DJ
        • Clark GM
        • Wong SG
        • et al.
        Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
        Science. 1987; 235: 177-182
        • Gusterson BA
        • Gelber RD
        • Price KN
        • et al.
        Prognostic importance of cerbB-2 expression in breast cancer.
        J Clin Oncol. 1992; 10: 1049-1056
        • Muss HB
        • Thor AD
        • Berry DA
        • et al.
        c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
        N Engl J Med. 1994; 330: 1260-1266
        • Colomer R
        • Montero S
        • Lluch A
        • et al.
        Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
        Clin Cancer Res. 2000; 6: 2356-2362
        • Baselga J
        • Seidman AD
        • Rosen PP
        • et al.
        HER2 overexpression and paclitaxel sensitivity in breast cancer: therapeutic implications.
        Oncology (Huntingt). 1997; 11: 43-48
        • Pauletti G
        • Dandekar S
        • Rong H
        • et al.
        Assessment of methods for tissuebased detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
        J Clin Oncol. 2000; 18: 3651-3664
        • Carter P
        • Presta L
        • Gorman CM
        • et al.
        Humanization of an anti-p185 HER2 antibody for human cancer therapy.
        Proc Natl Acad Sci U S A. 1992; 89: 4285-4289
        • Baselga J
        • Tripathy D
        • Mendelsohn J
        • et al.
        Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
        J Clin Oncol. 1996; 14: 737-744
        • Cobleigh MA
        • Vogel CL
        • Tripathy D
        • et al.
        Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
        J Clin Oncol. 1999; 17: 2639-2648
        • Vogel CL
        • Cobleigh MA
        • Tripathy D
        • et al.
        First-line Herceptin monotherapy in metastatic breast cancer.
        Oncology. 2001; 61: 37-42
        • Leyland-Jones B
        • Arnold A
        • Gelmon K
        • et al.
        Pharmacologic insights into the future of trastuzumab.
        Ann Oncol. 2001; 12: S43-S47
        • Slamon DJ
        • Leyland-Jones B
        • Shak S
        • et al.
        Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
        N Engl J Med. 2001; 344: 783-792
        • Seidman A
        • Hudis C
        • Pierri MK
        • et al.
        Cardiac dysfunction in the trastuzumab clinical trials experience.
        J Clin Oncol. 2002; 20: 1215-1221
        • Pegram MD
        • Lopez A
        • Konecny G
        • et al.
        Trastuzumab and chemotherapeutics: drug interactions and synergies.
        Semin Oncol. 2000; 27: 21-25
        • Hirsch FR
        • Helfrich B
        • Franklin WA
        • et al.
        Preclinical studies of gemcitabine and trastuzumab in breast and lung cancer cell lines.
        Clin Breast Cancer. 2002; 3: 12-16
        • Miller KD
        • Sisk J
        • Ansari R
        • et al.
        Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.
        Oncology (Huntingt). 2001; 15: 38-40
        • O'Shaughnessy J
        Gemcitabine and trastuzumab in metastatic breast cancer.
        Semin Oncol. 2003; 30: 22-26
        • Pegram MD
        • Finn RS
        • Arzoo K
        • et al.
        The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
        Oncogene. 1997; 15: 537-547
        • Bunn Jr, PA
        • Helfrich B
        • Soriano AF
        • et al.
        Expression of Her-2/neu in human lung cancer cell lines by immunohistochemistry and fluorescence in situ hybridization and its relationship to in vitro cytotoxicity by trastuzumab and chemotherapeutic agents.
        Clin Cancer Res. 2001; 7: 3239-3250
        • Konecny G
        • Slamon DJ
        HER2 testing and correlation with efficacy of trastuzumab therapy.
        Oncology (Huntingt). 2002; 16: 1576-1578
        • Blackstein M
        • Vogel CL
        • Ambinder R
        • et al.
        Gemcitabine as first-line therapy in patients with metastatic breast cancer: a phase II trial.
        Oncology. 2002; 62: 2-8
        • Carmichael J
        • Possinger K
        • Phillip P
        • et al.
        Advanced breast cancer: a phase II trial with gemcitabine.
        J Clin Oncol. 1995; 13: 2731-2736
        • Possinger K
        • Kaufmann M
        • Coleman R
        • et al.
        Phase II study of gemcitabine as first-line chemotherapy in patients with advanced or metastatic breast cancer.
        Anticancer Drugs. 1999; 10: 155-162
        • Gerson R
        • Serrano-O A
        • Villalobos A
        • et al.
        Gemcitabine response in advance breast cancer in relation to immunohistochemical factors.
        Proc Am Soc Clin Oncol. 2000; 19 (Abstract #572).: 145a
        • Valerio M
        • Cicero G
        • Armata M
        • et al.
        Gemcitabine (G) in pretreated breast cancer.
        Proc Am Soc Clin Oncol. 2001; 20 (Abstract #1953).: 51b
        • Brodowicz T
        • Kostler WJ
        • Moslinger R
        Single agent gemcitabine as second-and third-line treatment in metastatic breast cancer.
        Breast. 2000; 9: 338-342
        • Spielmann M
        • Llombart-Cussac A
        • Kalla S
        • et al.
        Single-agent gemcitabine is active in previously treated metastatic breast cancer.
        Oncology. 2001; 60: 303-307